BAXTER REPORTS SECOND-QUARTER 2024 RESULTS DEERFIELD, Ill., AUG. 6, 2024 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2024. "Baxter's strategic transformation continues to gain momentum and drive performance benefiting our broad range of stakeholders," said José (Joe) E. Almeida, chair, president and chief executive officer. "In addition to delivering positive top-line and bottom-line results in Q2 2024, Baxter's portfolio of medically ess ...

For Immediate ReleasesChicago, IL – August 6, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Baxter International (BAX) , Henry Schein (HSIC) , and IDEXX Laboratories (IDXX) .Here are highlights from Tuesday’s Analyst Blog:What's in Store for These 3 MedTech Stocks in Q2 Earnings?Medical sector players that have ...

Analysts on Wall Street project that Baxter International (BAX) will announce quarterly earnings of $0.66 per share in its forthcoming report, representing an increase of 20% year over year. Revenues are projected to reach $3.74 billion, increasing 1% from the same quarter last year.Over the last 30 days, there has been a downward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial for ...

Baxter International Inc. (BAX) announced the launch of its Helion Integrated Surgical System in Thailand. This innovative system leverages advanced operating room integration (ORI) to simplify the complexities of surgical environments. By enhancing OR efficiency and enabling surgical teams to stay focused and connected, the Helion system represents a significant advancement in medical technology.The Helion Integrated Surgical System was launched by Hillrom in the U.S. market in 2021. Besides Thailand, the ...

Core Viewpoint - The healthcare sector remains attractive for growth and income due to inelastic demand for products and services, with Baxter International becoming a more appealing investment following a significant decline in stock valuation [2][5]. Company Background and Recent Earnings Results - Baxter International develops and sells a variety of healthcare products, including medical devices and connected care service devices, utilized in various care facilities [6]. - For Q1 2024, Baxter reported revenue of $3.6 billion, a decrease of 1.6% year-over-year, but slightly above analyst expectations. Adjusted earnings-per-share increased to $0.65 from $0.59 in the prior year, exceeding expectations by $0.02 [6][10]. - All segments showed growth except for Healthcare Systems & Technologies, which faced order delays and tough comparisons [7][8]. Segment Performance - Medical Products & Therapies revenue grew by 6% to $1.229 billion, while Healthcare Systems & Technologies revenue fell by 9% to $667 million. Kidney Care revenue increased by 3% to $1.102 billion [9]. - Despite challenges, the adjusted operating margin expanded by 180 basis points to 14.3% due to strong performance in Kidney Care and Medical Products & Therapies [9][11]. Future Guidance and Earnings Outlook - Baxter raised its full-year adjusted earnings-per-share guidance to a range of $2.88 to $2.98, up from a previous range of $2.85 to $2.95, with revenue growth projected at 2% to 3% in constant currency [10][14]. - Analysts expect double-digit earnings growth for 2024, with a compound annual growth rate of 8.2% since the spinoff of its biotech business in 2015 [14][15]. Dividend and Valuation Analysis - Baxter has a strong history of returning capital to investors, with a current annual dividend payment of $1.16 and a payout ratio of 40%, which is higher than the average since 2019 but still reasonable [16]. - The stock currently yields 3.4%, significantly above its five-year average of 1.8%, attributed to a decrease in share price. Baxter trades at a forward price-to-earnings ratio of 11.6, well below its historical average of 20 [16][19]. - The potential sale of its Kidney Care business, which has low margins, could improve overall profitability and support the dividend [16][19]. Final Thoughts - Baxter's stock has underperformed over the past year, leading to a valuation that is nearly half of its historical trading levels. The planned divestiture of its lowest margin business is expected to enhance focus on more profitable segments [19]. - With earnings estimates indicating sustainable double-digit growth, there is potential for multiple expansion, making Baxter an attractive value play in the medtech sector [19].

Shares of Baxter International Inc (NYSE:BAX) are down 2.9% at $34.28, after a downgrade from Morgan Stanley to "underweight" from "equal weight," with a price-target cut to $30 from $39. The firm raised concerns over the medical equipment name's margin goals, noting its financial outlook may be more challenging than previously thought, particularly after its acquisition of Hillrom. On the charts, support at the $33 level kept losses in check over the past couple months. However, overhead pressure at the 60 ...

Company Overview - Baxter International's shares have increased by 2.4% in the first seven trading sessions of July after a decline of 13.5% in the first half of 2024, primarily due to inflationary pressures and reduced ESRD patient volume in China [1] - The company's share price recovery in July is linked to discussions with Carlyle Group regarding the potential sale of its kidney care business, which has been in preparation since last year [1][2] Financial Performance - Year-to-date, Baxter's shares have decreased by 11.4%, contrasting with the industry's growth of 0.8% and the S&P 500 Index's increase of 17.7% during the same period [1] - The kidney care segment, which generates over 30% of Baxter's total business quarterly, is being targeted for divestment, with Carlyle Group expected to offer more than $4 billion for the acquisition [2] Strategic Actions - The potential sale of the kidney care segment, named Vantive post-divestment, is anticipated to reduce Baxter's debt levels and enhance cash resources for capital expenditures [3] - Baxter's strategic plans announced in January 2023 include enhancing operational effectiveness and driving shareholder value, which has already seen the divestment of its BioPharma Solutions business for $4.25 billion [3] Future Outlook - A leaner business model post-separation is expected to improve Baxter's performance, with lower debt levels likely reducing interest expenses and boosting net margins [5] - Factors such as increasing hospital admissions and rising procedural volumes are projected to positively impact Baxter's prospects in 2024, supporting a continued recovery in share price [5]

Core Insights - The article emphasizes the importance of value investing and highlights the use of Zacks Rank and Style Scores to identify strong value stocks [1] Company Analysis: Baxter International (BAX) - Baxter International (BAX) has a Zacks Rank of 2 (Buy) and an A for Value, indicating strong potential [2] - BAX's current P/E ratio is 11.44, significantly lower than the industry average of 19.94 [2] - The Forward P/E for BAX has fluctuated between 10.64 and 15.91 over the past 52 weeks, with a median of 13.14 [2] - BAX's PEG ratio stands at 1.73, compared to the industry's average PEG of 1.97, indicating favorable growth expectations [2] - The PEG ratio for BAX has ranged from 1.63 to 4.33 in the past year, with a median of 2.26 [2] Company Analysis: Phibro Animal Health (PAHC) - Phibro Animal Health (PAHC) is rated 1 (Strong Buy) with a Value score of A, suggesting it is also a strong value stock [3] - PAHC's forward earnings multiple is 11.81, which is lower than the industry average P/E of 19.94 [3] - The PEG ratio for PAHC is 4.41, significantly higher than the industry average of 1.97 [3] - Over the last 12 months, PAHC's P/E has varied from 8.01 to 15.18, with a median of 10.56 [3] - PAHC's P/B ratio is 2.53, compared to the industry's price-to-book ratio of 6.77, indicating it may be undervalued [4] - The P/B ratio for PAHC has fluctuated between 1.42 and 2.78 over the past year, with a median of 1.89 [4] Conclusion - Both Baxter International and Phibro Animal Health exhibit strong value characteristics, suggesting they may be undervalued in the current market [4]

Shares of Baxter International (BAX) have gained 2.8% since Jun 26, after the company announced the recall of its Life2000 Ventilation System. Though the share price had declined following the news, it recovered following reports of potential discussion on divestment of BAX’s kidney care segment.The device, a portable ventilator for patients suffering from chronic respiratory failure or other breathing issues, has been recalled by Baxter. The recall follows the detection of damaged battery charger dongles, ...

Core Insights - Zacks Premium provides tools for investors to enhance their stock market engagement and confidence through various research services [1] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, helping investors identify securities likely to outperform the market in the short term [2] - Each stock is assigned a rating from A to F, with A indicating the highest potential for outperformance [2] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [2] Growth Score - The Growth Style Score assesses a company's financial health and future outlook by analyzing projected and historical earnings, sales, and cash flow [3] Momentum Score - The Momentum Style Score evaluates stocks based on price trends and earnings estimate changes, aiding investors in timing their purchases of high-momentum stocks [3] VGM Score - The VGM Score combines the Value, Growth, and Momentum Scores to identify stocks with the best overall potential [4] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to help investors build successful portfolios, with 1 (Strong Buy) stocks yielding an average annual return of +25.41% since 1988 [5] - There are over 800 stocks rated 1 or 2, which can be overwhelming for investors [5] Stock to Watch: Baxter International (BAX) - Baxter International Inc. is a global medical technology company with a presence in over 100 countries, focusing on products and digital health solutions for healthcare organizations [7] - BAX currently holds a 3 (Hold) rating on the Zacks Rank and has a VGM Score of A, indicating strong potential [7] - The company has a Value Style Score of A, supported by a forward P/E ratio of 11.4, making it attractive to value investors [7] - Analysts have recently revised BAX's earnings estimate upwards, with the Zacks Consensus Estimate increasing by $0.02 to $2.91 per share for fiscal 2024 [7]